M&A Deal Summary

Oragenics Acquires Biodextris

On March 9, 2021, Oragenics acquired life science company Biodextris

Acquisition Highlights
  • This is Oragenics’ 2nd transaction in the Life Science sector.
  • This is Oragenics’ 1st transaction in Canada.
  • This is Oragenics’ 1st transaction in Quebec.

M&A Deal Summary
Date 2021-03-09
Target Biodextris
Sector Life Science
Buyer(s) Oragenics
Deal Type Add-on Acquisition

Target

Biodextris

Laval, Quebec, Canada
Biodextris, Inc. is a contract research organization providing a suite of analytical, process development and CMC consulting services for vaccines and biologics in the clinical stages of development. Biodextris is based in Laval, Quebec.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Oragenics

Tampa, Florida, United States
Category Company
Founded 1996
Sector Life Science
Employees5
Revenue 14M USD (2022)
DESCRIPTION

Oragenics is a developer of of novel antibiotics against infectious disease and developing effective treatments for oral mucositis. Oragenics was founded in 1996 and is based in Tampa, Florida.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-04 Noachis Terra

United States

Noachis Terra, Inc. develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).

Buy $2M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-10-05 Odyssey Health - Neurological Drug Technology

Las Vegas, Nevada, United States

Odyssey Health's Neurological Drug Technology includes proprietary neurological drug therapies and technologies.

Buy -
Mergr

Product

Company

Legal